TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12670816
Drug: Epidural 10
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 10 mL saline injection
Study: 8595991
Drug: Drug combinations
Normalized name: Other anti-dementia drug combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combinations for Helicobacter pylori eradication
Study: 1572460
Drug: Thrombolysis (TL)
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis (TL) using 30 mg rt-PA
Study: 12791814
Drug: Valsartan (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40-80 mg/d)
Study: 6203784
Drug: Serial hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serial hormone determinations (beta‐hCG, HPL, P, 17‐OHP, E2 and E3)
Study: 6203784
Drug: Combined determination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined determination of all hormones
Study: 30047816
Drug: Pharmaceutical Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Care (PC) group
Study: 7598243
Drug: metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10 mg
Study: 12402733
Drug: Esmolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 80 mg
Study: 7709938
Drug: Current treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatments for osteoporosis
Study: 7709938
Drug: Preventive treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatments
Study: 2062395
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation (optimal medical treatment, training of physical endurance, health education, psychological and social support) for 3 months, 38 hours a week
Study: 24158248
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1,800 mg daily plus statin (EPA group, n = 40)
Study: 8570263
Drug: Amiloride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10 mg oral dose)
Study: 2212182
Drug: Comprehensive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive community programming for drug abuse prevention (school, parent, mass media, and community organization)
Study: 30520977
Drug: Twice-daily chemoradiotherapy
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily chemoradiotherapy (45 Gy in 30 fractions)
Study: 28251321
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg/kg diluted in normal saline up to 2 cc total volume injected before surgery
Study: 23241931
Drug: Meriva (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meriva (2 tablets/day, 2 x 500 mg of Meriva/day, corresponding to 2 x 100 mg curcumin/day)
Study: 11699613
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg once daily for 8 days
Study: 9591497
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (2 mg of estradiol on days 1‐12, 2 mg of estradiol plus 1 mg of norethisterone acetate on days 13‐22, and 1 mg of estradiol on days 23‐28; n = 21)
Study: 9591497
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (50 microg/d of estradiol on days 1‐28 followed by 250 microg/d of norethisterone acetate on days 14‐28; n = 21)
Study: 9591497
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (50 microg/d of estradiol on days 1‐28 followed by 250 microg/d of norethisterone acetate on days 14‐28; n = 10 female smokers)
Study: 11531899
Drug: Sumatriptan 6
Normalized name: sumatriptan 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 6 mg
Study: 3348073
Drug: Morphine-scopolamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-scopolamine 0.15 mg kg‐1 and 0.0065 mg kg‐1
Study: 29277968
Drug: Insulin monotherapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin monotherapy (placebo)
Study: 27374748
Drug: Alisporivir (Debio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (Debio 025) in combination with pegylated interferon‐α2a
Study: 26359998
Drug: High-potency topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency topical corticosteroid (betamethasone dipropionate)
Study: 2435071
Drug: Metoprolol (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (daily dose up to 200 mg) without invasive testing (group II)
Study: 6127501
Drug: Vitamin-D therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-D therapy
Study: 30591031
Drug: Valerian capsules
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian capsules
Study: 11836281
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg TU im at wk 2, 6, 12, and 18 combined with 400 mg NETE im at wk 0, 6, 12, and 18 (group II)
Study: 11836281
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg TU im at wk 2, 6, 12, and 18 with daily oral NET acetate (NETA) from wk 0 to 24 (group III)
Study: 29270003
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of telmisartan 40 mg and S-amlodipine 5 mg
Study: 29270003
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (FDC and concomitant administration)
Study: 23819227
Drug: Abdominal cluster‐needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal cluster‐needling therapy
Study: 19341989
Drug: Yoga classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga classes (twice weekly for 90 minutes over two months)
Study: 16881929
Drug: Multi-micronutrient Sprinkles
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient Sprinkles with 30 mg iron as ferrous fumarate
Study: 16881929
Drug: Multi-micronutrient Sprinkles
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient Sprinkles with 20 mg iron as ferric pyrophosphate
Study: 16881929
Drug: Iron drops
Normalized name: Iron Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron drops with 12.5 mg iron as liquid ferrous sulphate
Study: 15450574
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m(2)) and docetaxel (60 mg/m(2)) chemotherapy prior to surgery (neoadjuvant group)
Study: 15450574
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgery without any previous chemotherapy)
Study: 11264760
Drug: Budesonide 100
Normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 100 microg twice daily via Turbuhaler
Study: 11264760
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 400 microg daily via pMDI
Study: 11264760
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg daily via Turbuhaler
Study: 2679681
Drug: mezlocillin/oxacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin/oxacillin (2 g:1 g)
Study: 1099501
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy consisting of DTIC with adriamycin, CCNU, or hydroxyurea.
Study: 1099501
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with adriamycin and DTIC.
Study: 23851972
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Study: 22240882
Drug: Total occlusive
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total occlusive ionic silver‐containing dressing (TOISD) combination
Study: 9236571
Drug: Tacrine hydrochloride
Normalized name: Tacrine Hydrochloride
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrine hydrochloride (160 mg/d)
Study: 3652281
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (two 200 mg doses daily for 7 days)
Study: 31065701
Drug: DAILY (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAILY (every day feeding)
Study: 25136887
Drug: IV bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus regadenoson injection (400 µg)
Study: 10817799
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg intravenous administration)
Study: 9007147
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCP) administered for 28-42 days followed by menotropin treatment
Study: 1800877
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of fentanyl combined with diazepam
Study: 30849239
Drug: 140 ml
Normalized name: syringe, disposable, 140 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 ml of 'BEET It sport®' NO3‐ shot
Study: 31062253
Drug: gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin 300 mg
Study: 19393845
Drug: acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1000 mg
Study: 27787564
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (72 mg total, equivalent to 20 ounces of cranberry juice) administered once a day
Study: 27787564
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once a day
Study: 11207693
Drug: 585 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585 nm pulsed dye laser treatment
Study: 10757250
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg
Study: 30047564
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) and Velpatasvir (VEL) quantified using a novel LC–MS/MS method; dosage and duration not specified.
Study: 11196405
Drug: Fall‐Asleep Pacifier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent, containing NaF 0.25 mg, xylitol 159 mg, sorbitol 153 mg)
Study: 11196405
Drug: Fluoride tablets
Normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride tablets (Fludent) crushed in food
Study: 11196405
Drug: Fall‐Asleep Pacifier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent)
Study: 31758195
Drug: Colistin-meropenem combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin-meropenem combination therapy
Study: 30476654
Drug: Colistin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin monotherapy
Study: 28734907
Drug: Oral second
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral second generation antipsychotic
Study: 25020050
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose MenC‐TT at 3 months
Study: 25020050
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 doses of MenC‐CRM197
Study: 25020050
Drug: No primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No primary MenC doses
Study: 20397594
Drug: Manipulated information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated information about an agent's mental intentions
Study: 8624384
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of antibiotic therapy
Study: 25754845
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (no MBP)
Study: 22268969
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of isoflavones daily from Soylife 40
Study: 21072892
Drug: Regular liver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular liver treatment only
Study: 18765394
Drug: Percutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous continuous aortic flow augmentation (flow ≤1.5 L/min for up to 96 hours) plus medical therapy
Study: 15772912
Drug: Alvimopan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 0.5 mg
Study: 27996371
Drug: Combined maneuver
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined maneuver (injection of local anesthesia at the incision site, low‐pressure pneumoperitoneum, active gas suction, and pulmonary recruitment)
Study: 22033001
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 4) - no haemostatic agent applied
Study: 36118
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prenalterol
Study: 36118
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg prenalterol
Study: 28229390
Drug: 0.3 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1 body mass NaHCO3 (SBC3a and b)
Study: 23587162
Drug: Peretinoin 600
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peretinoin 600 mg daily
Study: 17078309
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) treatment
Study: 10762505
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure (NCPAP) treatment during the first night
Study: 20919542
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a hypercalorie formula and a fiber‐containing formula with erythromycin stimulation within the first 3 days.
Study: 2210865
Drug: IgG-anti-LPS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG-anti-LPS therapy
Study: 412207
Drug: Atenolol =
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol = 50 mg t.d.s.
Study: 412207
Drug: Methyl dopa
Normalized name: Methyl dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl dopa = 250 mg t.d.s.
Study: 28092069
Drug: Antimuscarinics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinics and beta‐3 adrenergic agonists (alone or in combination with standard BPE/BPO therapy)
Study: 28092069
Drug: Standard alpha‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard alpha‐adrenergic blockade and 5‐alpha reductase inhibitor therapy
Study: 21561398
Drug: Memantine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine plus rivastigmine patch
Study: 16430026
Drug: Citalopram-ratiopharm film-coated
Normalized name: citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram-ratiopharm film-coated tablets (test preparation)
Study: 16430026
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of a reference preparation (control)
Study: 12793516
Drug: Manual Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Assisted Cognitive-Behaviour Therapy (MACT)
Study: 3079010
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg three times daily
Study: 2711919
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for 2 weeks
Study: 1514339
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg/kg
Study: 889650
Drug: Althesin 0.055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althesin 0.055 ml/kg
Study: 861118
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg/kg
Study: 889650
Drug: Pethidine 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.7 mg/kg after intubation
Study: 27335011
Drug: Tracer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracer group (1 ml carbon nanoparticle suspension)
Study: 708150
Drug: GOBA 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOBA 1.0 g
Study: 26035319
Drug: HBV monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV monotherapy with either lamivudine or emtricitabine, N=56
Study: 18030086
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and CBT
Study: 19723787
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment during follow-up (naturalistic follow-up)
Study: 23896011
Drug: Acetaminophen 1
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g
Study: 16698862
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg + Acetaminophen 1 g
Study: 14507834
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored IVM treatments (control group)
Study: 10775962
Drug: Nicardipine (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (intravenously 5 mg/hour for one week)
Study: 1331482
Drug: High-dose carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carboplatin and etoposide with autologous bone marrow transplantation plus oxazaphosphorine (usually cyclophosphamide)
Study: 3858229
Drug: Xylitol-containing dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol-containing dentifrice (10% xylitol) with conventional treatment
Study: 3858229
Drug: Fluoride systemic
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride systemic administration (in milk or drinking water) with conventional treatment
Study: 3858229
Drug: Conventional dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dental treatment procedures alone (fluoride-free dentifrices)
Study: 10386022
Drug: PVP-I nasal
Normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVP-I nasal inhalation and gargling (1% PVP-I solution, 2 times/day for 2 weeks)
Study: 11718517
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg zopiclone
Study: 30609439
Drug: TG-C (TissueGene-C)
Normalized name: TG-C
DrugBank: TG-C (DB06004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG-C (TissueGene-C) at a dose of 3.0 × 10^7 cells
Study: 21422117
Drug: AS03-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted influenza H1N1/A/09 vaccine (1 dose)
Study: 21422117
Drug: AS03-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted influenza H1N1/A/09 vaccine (2 doses)
Study: 16598442
Drug: nCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP treatment in hypertensive OSAS patients
Study: 15381595
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of intravenous amoxicillin‐clavulanic acid
Study: 10703931
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (2 IU/m2/day = 0.67 mg/m2/day)
Study: 8397723
Drug: L-dihydroxy-phenylalanine/carbidopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dihydroxy-phenylalanine/carbidopa (100 mg/25 mg)
Study: 1902404
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin therapy
Study: 11770190
Drug: Climodien (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodien (estradiol valerate 2 mg plus dienogest 2 mg)
Study: 2941206
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 or 4 mg/day)
Study: 2941206
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 or 80 mg/day)
Study: 29506970
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine Monohydrate 15 g daily
Study: 29506970
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine Monohydrate (10 g or 15 g)
Study: 27437723
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy (MT group, n=9), therapy with a mirror box 5 days/week, 30 min/day, for 3 weeks
Study: 27437723
Drug: Electromyography-triggered neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyography-triggered neuromuscular stimulation (ES group, n=7), therapy of similar duration and frequency as MT group
Study: 25493602
Drug: PrEP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using DMPA
Study: 25493602
Drug: PrEP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using no hormonal contraception
Study: 25493602
Drug: PrEP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used DMPA
Study: 25493602
Drug: PrEP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used no hormonal contraception
Study: 12354427
Drug: l-NMMA (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NMMA (0.3 mg/kg/min intravenously)